Safety and clinical efficacy of IOA-289, a novel autotaxin inhibitor, plus gemcitabine and nab-paclitaxel (GnP) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)

被引：0
|
作者：
Melisi, Davide
Quinzii, Alberto
Valente, Monica
Di Giacomo, Anna Maria
Amato, Giovanni
Simonetti, Elena
Zecchetto, Camilla
Casallino, Simona
Leta, Luigi
Messineo, Luisa
Mendo, Lucia
Hammett, Tracey
Deken, Marcel
Di Conza, Giusy
Kaur, Paramjit
Lahn, Michael M. F.
Maio, Michele
机构：
[1] Univ Verona, Verona, Italy
[2] Azienda Osped Univ Integrata, Verona, Italy
[3] Azienda Osped Univ Integrata, Invest Canc Therapeut Clin Unit, Verona, Italy
[4] Univ Hosp Siena, Ctr Immunooncol, Siena, Italy
[5] Univ Siena, Siena, Italy
[6] Azienda Osped Univ Senese, UOC Immunoterapia Oncol, Siena, Italy
[7] Azienda Osped Univ Integrata, Med Oncol Unit, Verona, Italy
[8] AOUI Verona, Dept Med, Digest Mol Clin Oncol Res Unit, Verona, Italy
[9] Univ Verona, Scuola Specializzaz Oncol Med, Verona, Italy
[10] iOnctura SA, Geneva, Switzerland
[11] iOnctura BV, Amsterdam, Netherlands
[12] iOnctura, Geneva, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15130
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of sitagliptin, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC)
    Zhou, Tianxing, Sr.
    Wang, Xiuchao, Sr.
    Yang, Chao, Sr.
    Yu, Jun, Sr.
    Hao, Jihui
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma
    Wenjie Liu
    Yuting Fang
    Chao Zhang
    Midan Xiang
    Lijuan Qi
    Aijiang Su
    Yongkun Sun
    BMC Gastroenterology, 25 (1)
  • [3] Efficacy and safety of Nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer
    Filipazzi, V.
    Dalu, D.
    Isabella, L.
    Tosca, N.
    Ferrario, S.
    Gambaro, A.
    Somma, L.
    Fasola, C.
    Pellegrini, I.
    Bombonati, G.
    Curcio, R.
    Damiani, E.
    Cattaneo, M. T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] Phase 1 trial of gemcitabine/nab-paclitaxel in combination with the autophagy inhibitor hydroxychloroquine in previously untreated patients with metastatic pancreatic adenocarcinoma.
    O'Hara, Mark H.
    Gallagher, Maryann
    Teitelbaum, Ursina R.
    Giantonio, Bruce J.
    Damjanov, Nevena
    Loaiza-Bonilla, Arturo
    Amaravadi, Ravi K.
    Heitjan, Daniel F.
    Vasilevskaya, Irina
    Von Hoff, Daniel D.
    Ramanathan, Ramesh K.
    Laheru, Dan
    De Jesus-Acosta, Ana
    Velculescu, Victor E.
    O'Dwyer, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study
    Jaime Feliu
    Mónica Jorge Fernández
    Teresa Macarulla
    Bartomeu Massuti
    Ana Albero
    José Federico González González
    Guillermo Quintero-Aldana
    Juan Ignacio Delgado-Mingorance
    Ana Fernández Montes
    Carmen García Piernavieja
    Manuel Valladares-Ayerbes
    Ana María López Muñoz
    Rebeca Mondéjar Solís
    Pilar Vicente
    Esther Casado Gonzalez
    Irene González Cebrián
    Guillermo López-Vivanco
    Cancer Chemotherapy and Pharmacology, 2021, 87 : 543 - 553
  • [6] Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study
    Feliu, Jaime
    Jorge Fernandez, Monica
    Macarulla, Teresa
    Massuti, Bartomeu
    Albero, Ana
    Gonzalez Gonzalez, Jose Federico
    Quintero-Aldana, Guillermo
    Ignacio Delgado-Mingorance, Juan
    Fernandez Montes, Ana
    Garcia Piernavieja, Carmen
    Valladares-Ayerbes, Manuel
    Lopez Munoz, Ana Maria
    Mondejar Solis, Rebeca
    Vicente, Pilar
    Casado Gonzalez, Esther
    Gonzalez Cebrian, Irene
    Lopez-Vivanco, Guillermo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (04) : 543 - 553
  • [7] Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarcinoma
    Pignon, Flore
    Turpin, Anthony
    Hentic, Olivia
    Coriat, Romain
    Salmon, Emma
    Baumgaertner, Isabelle
    Bertrand, Nicolas
    Levy, Philippe
    Rebours, Vinciane
    Hammel, Pascal
    de Mestier, Louis
    PANCREATOLOGY, 2021, 21 (06) : 1064 - 1070
  • [8] Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
    Zong, Yuan
    Peng, Zhi
    Wang, Xicheng
    Lu, Ming
    Shen, Lin
    Zhou, Jun
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 12657 - 12666
  • [9] NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
    Ferdinando De Vita
    Jole Ventriglia
    Antonio Febbraro
    Maria Maddalena Laterza
    Alessio Fabozzi
    Beatrice Savastano
    Angelica Petrillo
    Anna Diana
    Guido Giordano
    Teresa Troiani
    Giovanni Conzo
    Gennaro Galizia
    Fortunato Ciardiello
    Michele Orditura
    BMC Cancer, 16
  • [10] Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: BIBABRAX study.
    Feliu Batlle, Jaime
    Jorge Fernandez, Monica
    Macarulla, Teresa
    Massuti, Bartomeu
    Albero, Ana
    Gonzalez, Federico
    Quintero Aldana, Guillermo Alfonso
    Delgado Mingorance, J. Ignacio
    Fernandez Montes, Ana
    Garcia Piernavieja, Carmen
    Valladares-Ayerbes, Manuel
    Garcia Giron, Carlos
    Mondejar, Rebeca
    Vicente, Pilar
    Casado, Esther
    Gonzalez Cebrian, Irene
    Lopez-Vivanco, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345